Price changes for the PBS

24 October 2012

As announced by the Minister for Health on 24 October 2012, the Government has agreed to change the price of 11 medicines currently listed on the PBS, consistent with the recommendations of the Pharmaceutical Benefits Pricing Authority at its August 2012 meeting. These changes are due to take effect from 1 December 2012, subject to final arrangements being met by the suppliers of the medicines.

Price increases for the PBS

Bethanechol

(Uro-carb®)

For the treatment of urinary retention.

 

Calcium

(Cal-Sup®)

For the prevention of osteoporosis.

Dantrolene

(Dantrium®)

For the treatment of muscle spasms.

Doxepin

(Deptran®)

For the treatment of depression.

 

Indapamide

(Natrilix SR®)

For the treatment of high blood pressure.

 

Lamivudine

(Zeffix®, 3TC®)

For the treatment of hepatitis B infection and human immunodeficiency virus (HIV) infection in children.

 

Lincomycin

(Lincocin®)

For the treatment of serious bacterial infections.

 

Nafarelin

(Synarel®)

For the treatment of endometriosis and as part of in?vitro fertilisation (IVF) procedure.

Nitrofurantoin

(Macrodantin®)

For the treatment of urinary tract infections.

 

 Price decreases for the PBS

Cetrorelix

(Cetrotide®)

For the treatment of infertility in women as part of an assisted reproductive technique such as IVF. 

Ganirelix

(Orgalutran®)

For the treatment of infertility in women as part of an assisted reproductive technique such as IVF.